Association of Neutrophil- Lymphocyte Count Ratio and Microbial Infection in Hospitalized Patients

December 30, 2024 updated by: Asmaa Hamed Abdelwahed Mohamed, Assiut University

Microbial infection is one of leading cause of morbidity and mortality in the world. Bacteremia that result from microbial infection has mortality rate as high as 30% . Systemic infections that result from microbial infection is a generalized disease that progresses rapidly and can lead to high mortality. This infection sets in from a progression of various pathogenic microorganisms that enter the bloodstream, reproduce and then release toxins and metabolites . Early diagnosis of microbial infection is essential for treatment. Culturing microorganisms is the most definitive way to confirm bacterial infections. Unfortunately, this gold standard is time consuming and may take from 24 to 48 hours and sometimes up to a week. A number of rapid initial indicators of microbial infection have been proposed, including C-reactive protein, neutrophil count, and white blood cell count. However, these criteria do not always reliably distinguish between severe bacterial, fungal, and viral infections . Therefore, the neutrophil-to-lymphocyte ratio (NLCR), a simple ratio between the number of neutrophils and lymphocytes measured in peripheral blood, has been proposed as a biomarker that combines two aspects of the immune system: the innate immune response, which is mainly driven by neutrophils, and adaptive immunity, supported by lymphocytes . This study aims to determine the diagnostic value of the neutrophil-to-lymphocyte ratio (NLCR) as an indicator of microbial infection, using complete blood count to determine the ratio in addition to culture and sensitivity according to the site of infection.

the aim of this study is to Investigating the association between neutrophil-lymphocyte count and the presence of microbial infection in the hospitalized patients.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Microbial infection is one of leading cause of morbidity and mortality in the world. Bacteremia that result from microbial infection has mortality rate as high as 30% . Systemic infections that result from microbial infection is a generalized disease that progresses rapidly and can lead to high mortality. This infection sets in from a progression of various pathogenic microorganisms that enter the bloodstream, reproduce and then release toxins and metabolites . Early diagnosis of microbial infection is essential for treatment. Culturing microorganisms is the most definitive way to confirm bacterial infections. Unfortunately, this gold standard is time consuming and may take from 24 to 48 hours and sometimes up to a week. A number of rapid initial indicators of microbial infection have been proposed, including C-reactive protein, neutrophil count, and white blood cell count. However, these criteria do not always reliably distinguish between severe bacterial, fungal, and viral infections . Therefore, the neutrophil-to-lymphocyte ratio (NLCR), a simple ratio between the number of neutrophils and lymphocytes measured in peripheral blood, has been proposed as a biomarker that combines two aspects of the immune system: the innate immune response, which is mainly driven by neutrophils, and adaptive immunity, supported by lymphocytes . This study aims to determine the diagnostic value of the neutrophil-to-lymphocyte ratio (NLCR) as an indicator of microbial infection, using complete blood count to determine the ratio in addition to culture and sensitivity according to the site of infection.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Asmaa Hamed Abdelwahed Mohamed, residant doctor
  • Phone Number: +201019844307
  • Email: asmaa26hamed@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All cases diagnosed with microbial infections at Assiut university hospitals.

Description

Inclusion Criteria:

  • age more than 18 years old
  • both sex
  • conformed diagnosis with micorbial infection

Exclusion Criteria:

  • Immunodeficiency patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
microbial infections cases
All cases diagnosed with microbial infections at Assiut university hospitals

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
neutrophil-lymphocyte count ratio
Time Frame: baseline
neutrophil-lymphocyte count ratio in the hospitalized patients with microbial infection
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

December 30, 2024

First Submitted That Met QC Criteria

December 30, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 30, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • N-L count ratio microbial inf

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe